This company has been marked as potentially delisted and may not be actively trading. Akers Biosciences (AKER) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock AKER vs. MYMD, NAVB, VNRX, CYCN, SSY, ARTL, BCLI, GNPX, ALZN, and ACXPShould you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), VolitionRx (VNRX), Cyclerion Therapeutics (CYCN), SunLink Health Systems (SSY), Artelo Biosciences (ARTL), Brainstorm Cell Therapeutics (BCLI), GENPREX (GNPX), Alzamend Neuro (ALZN), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "medical" sector. Akers Biosciences vs. Its Competitors MyMD Pharmaceuticals Navidea Biopharmaceuticals VolitionRx Cyclerion Therapeutics SunLink Health Systems Artelo Biosciences Brainstorm Cell Therapeutics GENPREX Alzamend Neuro Acurx Pharmaceuticals Akers Biosciences (NASDAQ:AKER) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment. Does the media prefer AKER or MYMD? In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score. Company Overall Sentiment Akers Biosciences Neutral MyMD Pharmaceuticals Neutral Which has preferable earnings & valuation, AKER or MYMD? Akers Biosciences has higher revenue and earnings than MyMD Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkers Biosciences$1.58M1.00-$3.89MN/AN/AMyMD PharmaceuticalsN/AN/A-$4MN/AN/A Which has more volatility & risk, AKER or MYMD? Akers Biosciences has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Is AKER or MYMD more profitable? Akers Biosciences' return on equity of -87.42% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Akers BiosciencesN/A -87.42% -73.31% MyMD Pharmaceuticals N/A -179.05%-108.14% Do institutionals & insiders have more ownership in AKER or MYMD? 5.5% of Akers Biosciences shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 0.3% of Akers Biosciences shares are held by company insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAkers Biosciences beats MyMD Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Akers Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKER vs. The Competition Export to ExcelMetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.58M$18.56M$5.75B$9.57BDividend YieldN/AN/A4.54%4.09%P/E RatioN/AN/A30.3724.92Price / Sales1.0020.51414.56174.73Price / CashN/AN/A37.3459.16Price / Book0.020.018.936.26Net Income-$3.89M-$15.34M$3.26B$265.47M Akers Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKERAkers BiosciencesN/A$0.09-7.0%N/A-94.5%$1.58M$1.58M0.004High Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.11+13.5%N/A-94.3%$260KN/A0.006High Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-80.0%$50K$8.13K0.0010VNRXVolitionRx2.1762 of 5 stars$0.62flat$3.50+464.5%+11.1%$64.47M$1.31M-1.7280News CoverageAnalyst RevisionGap UpCYCNCyclerion Therapeutics2.6563 of 5 stars$2.40+10.6%N/A-13.3%$7.24M$2M-3.2430Positive NewsShort Interest ↓SSYSunLink Health Systems2.3845 of 5 stars$0.91-2.9%N/A+38.1%$7.18M$32.44M3.811,376Gap UpARTLArtelo Biosciences2.8393 of 5 stars$9.72-3.1%$24.00+146.9%+31.0%$7.07MN/A-0.545Earnings ReportAnalyst ForecastShort Interest ↓BCLIBrainstorm Cell Therapeutics2.5057 of 5 stars$0.64+6.5%N/A-88.7%$7.06MN/A-0.1940Short Interest ↓GNPXGENPREX1.5047 of 5 stars$0.23+10.2%N/A-73.4%$7.05MN/A0.0020Earnings ReportShort Interest ↑ALZNAlzamend Neuro2.5766 of 5 stars$2.44+1.7%$180.00+7,277.0%-95.6%$6.95MN/A0.004Short Interest ↑ACXPAcurx Pharmaceuticals3.0142 of 5 stars$4.43-1.1%$31.00+599.8%-88.1%$6.89MN/A-0.413Analyst UpgradeGap Down Related Companies and Tools Related Companies MyMD Pharmaceuticals Alternatives Navidea Biopharmaceuticals Alternatives VolitionRx Alternatives Cyclerion Therapeutics Alternatives SunLink Health Systems Alternatives Artelo Biosciences Alternatives Brainstorm Cell Therapeutics Alternatives GENPREX Alternatives Alzamend Neuro Alternatives Acurx Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKER) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access